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Background: There is currently a need for high quality evaluations of new mobile health,
telehealth, smart pump and monitoring technologies undertaken in a pharmacy-related
setting. We aim to evaluate the use of these monitoring technologies performed in this
setting.
Methods: A systematic searching of English articles that examined the quality and the
design of technologies conducted in pharmacy-related facilities was performed using
the following databases: MEDLINE and Cumulative index to Nursing and Allied Health
Literature (CINAHL) to identify original studies examining the quality and the design of
technologies and published in peer-reviewed journals. Extraction of articles and quality
assessment of included articles were performed independently by two authors. Quality
scores over 75% are classed as being acceptable using a “relatively conservative” quality
benchmark. Scores over 55% are included using a “relatively liberal” cut-off point.
Results: Screening resulted in the selection of 40 formal evaluations. A substantial
number of studies (32, 80.00%) were performed in the United States, quantitative
in approach (33, 82.50%) and retrospective cohort (24, 60.00%) in study design.
The most common pharmacy-related settings were: 22 primary care (55.00%); 10
hospital pharmacy (25.00%); 7 community pharmacy (17.50%); one primary care and
hospital pharmacy (2.50%). The majority of the evaluations (33, 82.50%) reported
clinical outcomes, six (15.00%) measured clinical and economic outcomes, and one
(2.50%) economic only. Twelve (30.00%) quantitative studies and no qualitative study
met objective criteria for “relatively conservative” quality. Using a lower “relatively liberal”
benchmark, 27 quantitative (81.82%) and four qualitative (57.41%) studies met the lower
quality criterion.
Conclusion: Worldwide, few evaluations of mobile health, telehealth, smart pump and
monitoring technologies in pharmacy-related setting have been published.Their quality
is often below the standard necessary for inclusion in a systematic review mainly due to
inadequate study design.
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INTRODUCTION
Pharmacy is an evidence-based profession (Toklu, 2015).
Pharmacists are generally unwilling to recommend unproven
health technologies, especially when their adoption could
have negative unanticipated consequences (Sun and Qu,
2015). Evidence of effectiveness and cost-effectiveness is vitally
important for decision-makers (Dawoud and Baines, 2017). New
technologies often face adoption problems due to a scarcity of
suitable evidence (Van Gemert-Pijnen et al., 2011). A deficiency
of scientific studies is a widespread problem in all areas of
healthcare provision, including pharmacy (Chaudhry et al.,
2006; Atienza et al., 2010; Black et al., 2011; FIP/WHO, 2011).
There is a growing gap between the rate of technological
advance and the production of supporting evaluations. For
instance, there are now over 165,000 health-related apps available
on the main smartphone operating systems (The Economist,
2016). Few are launched with accompanying high-quality, peer-
reviewed evidence demonstrating their effectiveness and/or cost-
effectiveness (Steinhubl et al., 2015).
Technological innovation is important in all industries (Burns
and Stalker, 1961). For a pharmacy workforce that has been
relatively static for many decades, disruptive technological
change (a change that creates a new system and eventually
disrupts an existing system) could create a “technology shock”
(Spinks et al., 2016). Disrupting technologies can enhance
adaptability and flexibility, helping pharmacists to identify and to
solve unfamiliar problems in unfamiliar situations (Woods et al.,
2015). For instance, the profession could use smart packaging
to extend its surveillance of medicines taking (Darkins et al.,
2008; Sparks, 2011). As the widespread adoption of robotics
and bar-code technologies may soon reduce the number of
pharmacists involved in dispensing, pharmaceutical care may
be the way ahead (Hepler and Strand, 1990; Baines, 2015). In
response, we label (non-dispensing) technologies that enable
pharmacists to improve patient health and quality of life with
the name of “pharmaceutical care technologies.” We suggest that
mobile health (general term for the use of mobile phones and
other wireless technology to educate consumers about preventive
health care services), telehealth (the distribution of health-
related services and information via electronic information and
telecommunication technologies), smart pump (programmable
infusion device for controlling and administering intravenous
medicines) and monitoring technologies (e.g., microchip-
containing tablet blister for adherence monitoring) are amongst
this group of innovations.
With a deficit of available evidence, pharmacists do not always
have the information required to make rational technology
adoption decisions (Gregorio et al., 2013). Even when evaluation
studies are published, many are poorly designed and their low
quality can misguide decision-makers (Shuren and Califf, 2016).
To improve this situation, the constant production of well-
designed, high-quality evaluations is required. The first step in
improving the current situation is to evaluate the current state
of the technology appraisal literature that focuses on pharmacy
practice. This paper is a scoping review of the quality and the
design of evaluations of mobile health, telehealth, smart pump
and monitoring technologies performed in a pharmacy-related
setting. To our knowledge, no review has yet analyzed the quality
and the design of peer-reviewed evaluations of these technologies
in this setting. The rationale of this review is to help fill that gap.
METHODS
Scope of Review: Eligibility Criteria
A scoping review was undertaken to identify evaluations
of mobile health, telehealth, smart pumps and monitoring
technologies based upon the classification of technologies
identified by Goundrey-Smith (2013, 2014) The review assesses
the quality and the design of the identified studies. We limited
our search to studies written in English and did not restrict them
according to country. Studies had to measure either clinical or
economic outcomes, or both. The studies had to fall into our
defined technology categories. All study designs (including trials,
protocols) were included in the search process. However, only
evaluation studies were included in the final analysis.
This scoping review examined the quality and the design of
studies published in peer-reviewed journals that report scientific
evaluations of mobile health, telehealth, smart pump and
monitoring technologies tested in a pharmacy-related setting.
This paper is written from the point of view of pharmacy
practice research. The quality of the evaluations identified is
judged in terms of a composite quality score developed by Kmet
et al. (2004) which assesses study design in terms of structure,
methodology and outcomes measured. The main objectives of
our review are to: (i) identify all relevant studies published
in a peer-review journal that evaluate pharmaceutical care
technologies; (ii) evaluate the quality of this work; (iii) identify
the study designs and the clinical/economic outcomes used; (iv)
examine the link between study design and evaluation quality; (v)
outline the limitations of our review. To achieve these objectives,
we perform the following interlinked tasks. First, we outline our
review methods, including inclusion criteria and our approach to
quality scoring. Second, our results are presented, including data
on quality and design. Third, we discuss the main findings of the
review. Finally, we outline the limitations of our work.
Definitions
Hepler and Strand (1990) defined “pharmaceutical care” as
the “responsible provision of drug therapy for the purpose of
achieving definite outcomes that improve a patient’s quality
of life.” Subsequently, the board of the Pharmaceutical Care
Network Europe (Allemann et al., 2014) suggested that
“pharmaceutical care” may be defined as the “pharmacist’s
contribution to the care of individuals to optimize medicines use
and improve health outcomes.” Combining both definitions, we
define “pharmaceutical care technologies” as “technologies that
enable pharmacists to optimize medicines use and to enhance
patient health and quality of life.”
Information Sources
The following databases were searched: MEDLINE and
Cumulative index to Nursing and Allied Health Literature
(CINAHL) to identify studies published in peer-reviewed
journals between January 1, 2012 and December 31, 2016.
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Reference lists of articles identified in the search were included
and were subject to the same eligibility evaluation.
Searching and Screening
We searched the health technology literature using the key terms
suggested by Goundrey-Smith. All technology studies selected
included the secondary search terms: “pharmacy,” “pharmacist,”
or “pharmacies.” The search strategy for each database included
the concepts: pharmaceutical care technologies; pharmacy.
The former included the following terms derived from
Goundrey-Smith: “mobile health,” “monitoring technologies,”
“smart pump,” “smart packaging” and “telechealth.” Other
keywords associated with telehealth (suggested on EBSCO)
were included: “telemonitoring,” “teleconsultation,” “telecare,”
and “telemedicine.” Goundrey-Smith also discusses the potential
of mobile phone apps having an impact on pharmacy practice.
A range of search terms (suggested by EBSCO) associated
with mobile technology were included: “mHealth,” “m-health,”
“mobile health,” and “medical apps.” “Health technology,” and
“health information technology” were specified as umbrella
terms for other technologies not included in our list. For
our secondary search concept, “pharmacy” was defined as
“pharmacy,” “pharmacies,” or “pharmacist.” Titles and abstracts
were screened to remove studies that were clearly irrelevant to the
aim of the review (by IG and DB). The full texts of the remaining
original studies were then examined to determine eligibility.
Study Selection
Article titles and abstracts were screened independently by two
different authors, IG and DB against the inclusion and exclusion
criteria. Search results were imported into a Microsoft Excel and
manually screened by these authors to remove any duplicates.
Article titles were shortlisted for a detailed review of their
abstracts. Abstracts that seemed appropriate were then screened
for a full-text review. A quality assessment was performed on
the articles eligible for the review. Throughout this process, we
focused on articles published in English that were evaluations
in the categories of mobile health, telehealth, smart pumps and
monitoring technologies (the “comparisons”) of pharmaceutical
care technologies (the “interventions”) tested on patients and
staff (the “participants”) in a pharmacy-related setting. Study
protocols and reviews were not included.
Data Collection Process
Adata extraction table was created to collect relevant information
for each included study. The principal investigator extracted data
using a data extraction form (table format) that was verified by
the second reviewer. The extracted data included the name of the
author, year of publication, journal, place, methodology, sample
size, study design, intended market, primary outcome and study
type.
Quality Analysis
We analyzed the quality (the “outcome”) of this work and
reported the evaluation methods used (the “study design”).
To assess the quality of each paper, scoring was undertaken
using the criteria for evaluating primary research papers
developed by Kmet et al. For quantitative studies, a series of
14 questions are used to assess quality. These include questions
related to study design, methods of subject selection, random
allocation procedures, blinding of investigators, blinding of
subjects, outcome measures, sample size, estimates of variance,
confounding, reporting of results and the evidence base for the
conclusion. Each question is scored using the following options:
Yes (2 points), Partial (1 point), No (0 points), and N/A. The
equation for estimating the quality scores is: 28 minus (number
of N/A × 2). The figure of 28 is the maximum score possible for
the 14 questions, which can be given a maximum score of 2. We
calculated a quality score for 33 quantitative papers using this
method and report the results below.
As they will often use different methods to their quantitative
counterparts, Kmet et al. (2004) recommend a different means of
evaluating the quality of qualitative studies. Instead of 14, only 10
questions are used to assess the qualitative papers. The questions
assess study design, context of the study, sampling strategy, data
collection and methods of data analysis. Each question is scored
using the following options: Yes (2), Partial (1), and No (0).
This method includes a N/A option. The equation calculates the
summary score for qualitative study as follows: Total score/20.
The figure of 20 is the maximum score possible for 10 questions,
which can be given amaximum score of 2.We calculated a quality
score for the seven qualitative studies sampled.
The quality score system was developed to define a minimum
threshold for the inclusion of studies in systematic reviews. Kmet
et al. (2004) suggest two cut-points for article inclusion. Scores
over 75% are classed as being acceptable using a “relatively
conservative” quality benchmark. Scores over 55% are included
using a “relatively liberal” cut-off point. In this paper, we report
the number of quantitative and qualitative studies that meet the
conservative and liberal criteria. However, we do not exclude
papers from our analysis on this basis. Because we do not
intend to analyse the effectiveness of individual interventions at
a patient-level, the usual forms of bias do not apply to our review
(Higgins and Green, 2008).
RESULTS
Study Selection and Characteristics
As Figure 1 shows, our initial search led to a total of 4,377 results
(3,710 MEDLINE and 667 CINAHL). Following an analysis of
publication titles, 345 papers were manually screened for abstract
analysis. After reading the abstracts, 82 publications were selected
for full-text assessment. The full reading resulted in 42 papers
being deemed irrelevant to our review and 40 formal evaluations
were finally selected.
Table 1 shows that the studies identified had the following
characteristics. First, 32 out of 40 (80.00%) of the evaluations
reviewed were performed in the United States, followed by three
(7.50%) in the Netherlands. Second, 33 studies (82.50%) were
quantitative and seven (17.50%) qualitative. Third, amongst the
papers retrieved, the most common study designs employed were
(with % of frequency in brackets) retrospective cohort study (24,
60.00%) and randomized controlled trials (RCTs) (9, 22.50%).
Fourth, the intended setting for the technologies evaluated were:
22 primary care (55.00%); 10 hospital pharmacy (25.00%); 7
community pharmacy (17.50%); one primary care and hospital
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FIGURE 1 | Flow diagram of scoping review search.
pharmacy (2.50%). Finally, out of the 40 evaluations, 33 (82.50%)
reported clinical outcomes, six (15.00%) measured clinical and
economic outcomes, and one (2.50%) economic only.
Results by Technology Category
This review found that only a handful of evaluations were
published in each of the technology categories shown in
Table 2. First in the ranking is “telehealth” with twenty
studies (50.00%), followed by “mobile health” with nine
(22.50%). Then, “monitoring technologies” produced seven
(17.50%) studies. Finally, four papers (10.00%) evaluated “smart
pumps.”
Telehealth
Table 2 shows that 20 studies focused on telehealth. They include
evaluations of telehealth, telemedicine and telemonitoring.
Seventeen of the 20 studies sampled were American, with one
study each from Italy, Canada and the Netherlands. Three were
qualitative and 17 were quantitative. Nineteen sampled patients
to test their technologies; one sampled staff. Retrospective cohort
study was the most commonly used study design. Six out
of eight studies published were conducted in a primary care
setting, one took place in community pharmacy and the other
in hospital pharmacy. All studies specified a primary outcome.
Six undertook a clinical evaluation, one conducted a clinical and
economic evaluation and one performed an economic evaluation
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TABLE 1 | Summary characteristics of articles included in the review (n = 40).
Characteristics Studies (n, %)
COUNTRY
Australia (1, 2.50)
Canada (1, 2.50)
Italy (1, 2.50)
Spain (1, 2.50)
UK (1, 2.50)
Netherlands (3, 7.50)
USA (32, 80.00)
METHODS
Qualitative (7, 17.50)
Quantitative (33, 82.50)
STUDY DESIGN
Cross-sectional study (1, 2.50)
Economic evaluation (1, 2.50)
Non-randomized controlled trial (1, 2.50)
Prospective observational study (4, 10.00)
Randomized-controlled trial (9, 22.50)
Retrospective cohort study (11, 27.50)
Formative study (13, 32.50)
INTENDED MARKET
Primary care and hospital pharmacy (1, 2.50)
Community pharmacy (7, 17.50)
Hospital pharmacy (10, 25.00)
Primary Care (22, 55.00)
OUTCOME
Economic (1, 2.50)
Clinical and Economic (6, 15.00)
Clinical (33, 82.50)
only. All six of the clinical evaluations produced positive results.
The joint clinical and economic study was positive in both
dimensions and the stand alone economic study was negative.
Mobile Health
Table 2 shows that nine evaluations focused on mobile health
technologies. However, eight out of the nine studies were
conducted in the USA and one in the UK. Of the studies
published, three were qualitative and six were quantitative. Six
out of nine studies recruited patients to test their technologies.
Two studies used providers and another used patient medical
records. Three studies employed a retrospective cohort design,
five employed a formative design and one was a RCT. Five studies
were undertaken in a primary care setting, three in community
pharmacy and one in hospital pharmacy. All studies specified
a primary outcome and performed a clinical evaluation. No
economic or costing work was undertaken. Four of the nine
studies had negative results.
Monitoring Technologies
Table 2 shows that seven studies focused on monitoring
technologies, which includes smart packaging. All seven were
quantitative and used patients to test their technologies. Out
of these, three were formative, two were RCTs, one was a
prospective observational study and one was a retrospective
cohort study. Four studies were conducted in primary care alone,
one in community pharmacy, one in hospital pharmacy and one
jointly in primary care and hospital pharmacy. All the studies
specified a primary outcome and performed a clinical evaluation
of their chosen technology. No economic or costing studies were
performed. Five of the seven studies produced positive results.
Smart Pumps
Table 2 shows that four studies evaluated smart pumps. One
study was qualitative and the remaining three were quantitative.
Two studies sampled patients to test their technologies. One
evaluation focused on providers and the other performed a
system evaluation. A retrospective cohort design was used for
two studies. One was a formative evaluation and another was
a prospective observational study. All studies were conducted
in a hospital pharmacy setting and stated a primary outcome.
Two undertook clinical evaluations. Two conducted an economic
evaluation alongside clinical studies. All evaluations produced
positive findings.
Quality Assessment
Table 3 shows the quality scores for both quantitative and
qualitative studies. In terms of quality, 12 (30.00%) quantitative
studies and no qualitative study met the Kmet et al. (22) criteria
for “relatively conservative” quality. Using the lower “relatively
liberal” benchmark, 27 (67.50%) quantitative studies and four
(10.00%) qualitative study passed. The table also shows the
quality score for each of the 33 quantitative studies, which was
calculated using the Kmet et al. framework. The quantitative
summary scores vary from 39 to 88. Applying the conservative
benchmark of 75%, 21 (63.64%) out of the 33 quantitative
studies were of insufficient quality. If the standard is dropped,
using the 55% cut-off only six (18.18%) studies fail to meet
the required benchmark. Therefore, whether 15 (45.45%) studies
have acceptable quality depends upon which of the two cut-offs
is used.
Quality scores were also calculated for the seven qualitative
papers identified, which produced a range of 20–70. As Table 3
shows, using the conservative criteria only, no study was of
sufficient quality. Under the liberal criteria, four (57.14%) papers
managed to reach the required standard. Therefore, a switch
of criteria results in a difference of four (57.14%) papers being
acceptable in quality terms.
Study Quality and Design
Table 4 shows average quality scores by study design and
technology categories. The following quality scores were
obtained for quantitative studies: cross-sectional (77.00%);
economic evaluation (61.00%); formative (66.00%); non-
randomized controlled trial (86.00%); prospective observational
(74.67%); RCT (86.13%); retrospective cohort (70.11%).
The qualitative scores are: formative (52.50%); prospective
observational (60.00%). The sub-totals show that the average
quality score for quantitative studies is 64.97% and for qualitative
is 53.57%. The results also show quality scores by technology:
mobile health (67.89%); monitoring technologies (69.86%);
smart pumps (49.50%); telehealth (65.35%).
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DISCUSSION
Without sufficient evidence, novel technologies may fail to
be adopted in a pharmacy-related setting (Siska and Tribble,
2011). The review presented here suggests that, worldwide, few
evaluations of pharmaceutical care technologies are currently
being undertaken in such a place. With only 40 relevant studies
being identified over a 5-year period, the first finding of our
review is that pharmacy-related evaluations of new technologies
are relatively rare. This number is small, given the number of new
technologies that appear each year. However, in interpreting this
data, we must add the caveat that many of the health technologies
launched each year may be evaluated for general use in any
health setting, which covers pharmacy by default. For instance,
Dayer et al. (2013) reviews the potential benefits of Smartphone
medication adherence apps to patients and providers, but does
not undertake this work solely with pharmacist input or in a
pharmacy-related setting. Therefore, their paper did not appear
in our search. As this suggests, pharmacy specific evaluationsmay
not be needed for many new health technologies. Our search
is, consequently, narrow in its focus. Even if these caveats are
considered, the numbers of evaluations identified in this review
are still relatively low.
Whilst it is useful to speculate about the relative number
of papers published in this area, the main focus of this review
is study quality and design. Using the Kmet et al. (2004)
scoring system, we found a wide dispersion in the quality of
papers published. Only 30.00% of quantitative studies met the
higher, conservative benchmark. In comparison, no qualitative
studies achieved this quality standard. In a sector familiar
with high-quality evidence accompanying the launch of new
pharmaceutical products, new technologies with low quality
evidence may struggle to be adopted. Therefore, our third finding
is that the quality of most of evaluations we reviewed is lacking
when compared to objective criteria. As the Kmet et al. (2004)
scoring system is primarily based upon the quality of study
design, we suggest that inadequate study design is the cause
of these lower quality scores. This view is support by the data
presented in Table 4.
We classify pharmaceutical care technologies as including
mobile health, telehealth, smart pumps and monitoring
technologies. These technologies are pharmacy-enabling because
they extend the knowledge and the capabilities of pharmacists,
enabling them to create better outcomes for patients. This
category suggests that pharmaceutical care activities may be
enhanced by new health technologies, as well as an extension of
professional skills and roles (Lapão et al., 2013). Of the 40 papers
we identified, 33 were quantitative and 7 were qualitative. The
average quality score in the former group is (2144/33) = 64.97%
and (375/7) = 53.57% in the latter. Both these average scores are
below the Kmet et al. relatively conservative quality benchmark.
We discuss the evaluations in these classes below.
Telehealth is an enabling-technology for patients (Dewsbury
and Ballard, 2012). We found 20 studies relevant to pharmacy.
Margolis evaluates telemonitoring for home blood pressure
in hypertension care (Margolis et al., 2012). Similarly, Wang
performs an economic evaluation of telephone self-management
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TABLE 4 | Average percentage quality score by study design and technology.
Mobile
health (%)
Monitoring
technologies
(%)
Smart pump (%) Telehealth
(%)
Study design
average quality
score (%)
Quantitative studies
Cross-sectional study – – – 77 77.00
Economic evaluation – – – 61 61.00
Formative study 76 57.67 – 43.84 66.00a
Non-randomized controlled trial – – – 86 86.00
Prospective observational study – 86 55 83 74.67b
Randomized-controlled trial 71 84.5 - 74.83 86.13c
Retrospective cohort study 66 61 41.5 57.8 70.11d
Average of quantitative studies
per technology category
70.17 69.86 46 69.53 –
Qualitative studies
Formative study 63.33 – 60 32.5 52.50e
Prospective observational study – – – 60 60
Average of qualitative studies per
technology category
63.33 – 60 41.67 –
Average quality score of
qualitative and quantitative
studies per technology category
67.89 69.86 49.50 65.35 –
Sub-total of quantitative studies 64.97
Sub-total of qualitative studies 53.57
Sub-total of all studies 62.98
a(50+58+64+65+73+73+79)/7=66.00.
b (55+83+86)/3=74.67.
c(54+68+71+71+83+83+85+86+88)/8 = 86.13.
d (39+44+46+47+61+61+64+64+64+68+73)/9 = 70.11.
e(20+45+50+60+70+70)/6 = 52.50.
for blood pressure control (Wang et al., 2012). Margolis
examines the use of telepharmacy to improve inhaler adherence
in veterans with COPD (Margolis et al., 2013). Martinez
studies the implementation of a pharmacist-led heart titration
clinic that employs telemonitoring for the daily monitoring
of patient body weight (Martinez et al., 2013). Philip analyses
the expansion of clinical pharmacy through increased use
of outpatient pharmacists for anticoagulation services (Philip
et al., 2015). Verbosky assesses the implementation of diabetes
management via telehealth, whilst Owsley evaluates telemedicine
for diabetic eye screening (Owsley et al., 2015; Verbosky et al.,
2016). Singh studies the implementation and benefits of a
pharmacist-managed telehealth anticoagulation clinic (Singh
et al., 2015). Aberger evaluates a telehealth system that
incorporates home blood pressure monitoring (Aberger et al.,
2014). Brunetti describes the CAPITAL study, which focuses on
cardiovascular prevention with telecardiology (Brunetti et al.,
2016). Cole examines inpatient telepharmacy consultation and
medication errors (Cole et al., 2012). Desko evaluates a clinical
video telehealth pain management clinic (Desko and Nazario,
2014). Gordon investigates a telepharmacy initiative for cancer
patients (Gordon et al., 2012). Fortney evaluates telemedicine
collaborative care for depression (Fortney et al., 2015). Fortney
analyses telemedicine-based collaborative care for post-traumatic
stress disorder (Fortney et al., 2013). Kooy examines patient
satisfaction with telephone counseling by pharmacists and
medication refill adherence (Kooy et al., 2015). McFarland
examines the use of home telehealth monitoring by clinical
pharmacists with type 2 diabetic patients (McFarland et al.,
2012). Schneider evaluates the impact of telepharmacy through
medication errors (Schneider, 2013). Shane-McWhorter analyses
a pharmacist-provided diabetes management telemonitoring
program (Shane-McWhorter et al., 2015). Young investigates
patient and pharmacist telephone encounters with asthma
patients (Young et al., 2012).
The above studies suggest that telehealth technologies
employed in a pharmacy context focuses on communication
between pharmacists and patients. This is very different to
telecare as monitoring devices (such as pendant alarms) located
in patients’ own homes (Steventon et al., 2013; Roulstone,
2016). Therefore, greater clarity on the types and the benefits
of telehealth, telecare and telepharmacy would be useful for
guiding future pharmacy research and practice, particularly as
the use of this category of technology raises practical and ethical
issues (Mitka, 2013; Mort et al., 2013). Given the personalized
nature of this technology, all of the 20 studies identified recruited
patients to test their innovative technologies using a range
of study designs. The average quality scores for the studies
were: formative evaluations (51%); RCTs (75%); retrospective
cohort studies (58%); cross-sectional study (77%); economic
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evaluation (61%); prospective observational study (72%); non-
randomized controlled trial (86%). These results imply that the
quality standards achieved in this category of evaluation were
variable, with implications for the trustworthiness of the evidence
generated.
Our review identified nine papers evaluating mobile health
technologies (Steinhubl et al., 2015). Gustafson examines the
effects of a patient support system that includes monthly
phone calls carried out by pharmacists and other health
care professionals (Gustafson et al., 2012). Foreman assesses
the impact of text messaging to improve patient medication
adherence, whilst Snuggs analyses the use of texting to prevent
relapses in smoking (Foreman et al., 2012; Snuggs et al.,
2012). Burk examines a web-based app for medication use
in a veteran’s healthcare system (Burk et al., 2013). Andrus
assesses the accuracy of formulary information in both EHR
and the Epocrates mobile drug database application, used for
making medication selection decisions (Andrus et al., 2015).
Wilcox designed a personal health record application called
“myNYP inpatient” and assesses its usefulness for patients
(Wilcox et al., 2016). DiDonato evaluates patient perceptions of
a pharmacy mobile app for patient adherence (DiDonato et al.,
2015). Gatwood studies the impact of tailored text messages
on medication usage amongst diabetic patients (Gatwood et al.,
2016). Sarzynski uses beta-testing on a smartphone application
for medication adherence (Sarzynski et al., 2017).
Compared to the large number of health apps launched
annually, the handful of studies identified suggests that very
few mobile health technologies are reviewed formally in a
pharmacy setting. The absence of such scientific evaluations may
be evidence of a “valley of death” between product availability
and use in pharmacy practice (Wessner, 2005; Páez-Avilés
et al., 2015). For a profession keen on creating new roles and
opportunities, the failure to adopt new mobile technologies as
part of the pharmacist’s tool-kit may limit continued professional
growth (Miranda et al., 2014; Ventola, 2014). Of the studies
published, three studies employ a retrospective cohort design,
five employ a formative design and one is a RCT. Their average
quality scores are 66, 69, and 71%, retrospectively. These scores
suggest that improved study designs could generate higher
quality evidence in this category.
Seven studies were identified that evaluate monitoring
technologies in a pharmacy context (Speedie et al., 2008;
Fox et al., 2011). Van Onzenoort studies smart blister-pack
technology for checking patient adherence (Van Onzenoort
et al., 2012). Vasbinder assesses the relationship between
ethnicity and electronically measured adherence to inhaled
corticosteroids amongst children (Vasbinder et al., 2013). Zullig
pilots a medication calendar that incorporates reminders using
Meducation R© technology (Zullig et al., 2014). Chan evaluates
the effects of using electronic monitoring devices for adherence
to inhaled corticosteroids, whilst Migliozzi looks at controlling
blood pressure using home monitoring (Chan et al., 2015;
Migliozzi et al., 2015). Sayner compares self-reported adherence
data with information collected form a medication event
monitoring system (Sayner et al., 2015). Finally, Bender evaluated
the use of a novel technology to improve the adherence of
pediatric asthmatic patients (Bender et al., 2015). Combined,
these studies suggest that monitoring technologies have an
important role to play in enabling pharmacists to achieve better
outcomes for patients, particularly in relation to medication
adherence (Bosworth et al., 2011). However, the volume of
evidence generated is low given the potential benefits offered
by innovations in this category. Although all seven evaluations
are quantitative and involve patients, study designs are not
uniform: three are formative (50, 58, 65%); two are RCTs (83,
86%); one is a prospective observational study (86%); one is a
retrospective cohort study (61%). Their quality scores are shown
in the proceeding brackets.
Smart pumps are electronic infusion devices that have the
potential to reduce intravenous drug administration errors
(Franklin, 2017). Our review found four published studies.
Harding examines the use of smart pump drug libraries where
continuing education is provided for nurses and pharmacists
(Harding, 2012). Kennerly studies smart pumps for epidural
infusions, whilst Manrique-Rodriguez evaluates the impact of
introducing smart pumps into a pediatric intensive care unit
(Kennerly et al., 2012; Manrique-Rodríguez et al., 2013). Finally,
Gerhart combines the safety features of infusion pumps with
software that shows live infusion data (Gerhart et al., 2013). Smart
pumps are an important enabling technology for pharmacy
practice. However, our review creates a mixed message of
whether more studies are required. In our search terms, we
specified that evaluations must be performed in a pharmacy-
related setting. However, this category of technology may also
be identified as medicines or guidelines related, particularly in
the case of medication libraries containing dosing guidelines,
concentrations, clinical advice and the like. We conclude that
smart pumps are a vital technology in pharmacy practice, but
we have identified few evaluations in this category using our
key terms. In terms of study design, two evaluations employ
a retrospective cohort design (39%, 44%), one is a formative
evaluation (60%) and another is a prospective observational
study (55%). Relevant quality scores are in the brackets
shown.
First, health technology is a diverse field, which covers many
thousands of new innovations launched each year. We identified
a new class of studies, which we call “pharmaceutical care
technologies.” This division is innovative. More research is,
therefore, required to ascertain whether this novel categorization
is useful for pharmacy practice and research. Second, our
review focuses on technologies that enable pharmacists
and pharmacy practice. However, many technologies are
designed to enable patients (not their practitioners). Our
approach may be orthogonal to the intentions of many device
manufacturers, particularly when considering personalized
health apps. Therefore, further research is required to examine
the differences between practitioner- and patient-enabling
technologies in a pharmacy-related setting. Finally, we focus
on technologies suggested by Goundrey-Smith. We have not
searched for all possible health technologies that could be
adopted in a pharmacy-related setting. Notably, “wearables”
and the “internet of things” were not included in our review.
However, an initial search identified no relevant studies in the
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time-period we examined. As these new technologies grow in
influence, more comprehensive reviews of the literature will be
required.
IMPLICATIONS OF THE REVIEW FOR
PHARMACY PRACTICE
The technological innovations discussed have the potential
to improve pharmacy practice related tasks and functions.
In addition, evidence from included studies suggested that
the systems could be improved through innovation involving
technology. Pharmacists should not assume that all new health
technologies are automatically good for patients (Draper and
Sorell, 2013). Therefore, this review suggests that the process of
evaluating new health technologies should be continuous and
be of the highest research quality possible (Catwell and Sheikh,
2009;Wapner, 2016). Not only will high quality evidence support
the rational adoption of new pharmacy-enabling technologies,
but better evidence may help avoid some of the unintended
problems associated with the use of novel innovations (Patterson
et al., 2002; Koppel et al., 2008). To secure the future of
the profession, as technology evolves, pharmacy practice must
evolve, too (Baines, 2008).
CONCLUSIONS
This paper reviews the quality and the design of studies published
in peer-reviewed journals that report scientific evaluations
of new health technologies tested in a pharmacy-related
setting. The results suggest that, worldwide, few evaluations of
pharmaceutical care technologies are currently being undertaken.
With only 40 relevant studies being identified, the first finding
of our review is that pharmacy-based evaluations of new
technologies are relatively rare (not many have had a pharmacy
focus). Our second finding is that the quality of most of
the evaluations we reviewed was lacking when compared to
objective criteria. As the Kmet et al. scoring system is primarily
based upon the quality of study design, we can conclude that
inadequate study design may be a significant cause of these lower
quality scores. Despite the improvements in technology, there is
limited evidence on how this translates to real settings and to
consumer satisfaction. Most technology driven systems required
significant funding and support, particularly those involving
latest technology. Rigorous comparative studies are needed to
evaluate the effectiveness of different technologies.
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